# Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma

> **NCT02733380** · PHASE2 · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** Chidamide
- **DRUG:** Vinorelbine
- **DRUG:** Liposomal Doxorubicin or mitoxantrone
- **DRUG:** Dexamethasone
- **DRUG:** Thalidomide

## Key facts

- **NCT ID:** NCT02733380
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-05
- **Primary completion:** 2020-05
- **Final completion:** 2021-05
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02733380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02733380, "Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02733380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*